E-Learning

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC). NMIBC BCG Unresponsive Papillary Disease: ImmunityBio is preparing to submit a supplemental Biologics License Application (sBLA) in 2025 for its treatment targeting Bacillus Calmette-Guérin (BCG) unresponsive NMIBC in the papillary indication. As published in

Read more

BofA Floats Third Year of 20% S&P Gains in Market Surprises List

(Bloomberg) -- A third straight year of outsize gains in US stocks — a display of strength last seen in the 1990s — leads Bank of America Corp.’s list of potential market surprises for 2025.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyNYC Commuters Get New Way to Dodge Traffic: $95 Helicopter RidesWill Americans Ever Lose Their Taste for Telework?Chicago Agency Pitches $1.5 Billion Plan to Fix Transit WoesChurches, Cinemas — and Moon Artifacts — Top List of E

Read more

Goldman Sachs Stock May Be Pricey But Its One Of The Cheapest Ways For Investing In Capital Markets: Analyst

Keefe, Bruyette & Woods analyst David Konrad reiterated an Outperform rating on the shares of Goldman Sachs Group Inc (NYSE:GS) and raised the price forecast to $690 from $686. The analyst notes Goldman Sachs posted an impressive quarterly performance, fueled by substantial gains in trading and continued growth in Asset Management. According to the analyst, trading revenue surged 33% year-over-year despite a tough comparison, with equities remaining stable quarter-over-quarter amid usual seasona

Read more

Your 60/40 Portfolio Will Gain 3.5% Thanks to Bond Market Returns, Says Quant Giant

(Bloomberg) -- Quant giant AQR Capital Management has upgraded its expectations for the performance of a 60/40 portfolio in the years ahead, saying the classic investing approach is set to benefit from rising returns in the bond market.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyNYC Commuters Get New Way to Dodge Traffic: $95 Helicopter RidesChicago Agency Pitches $1.5 Billion Plan to Fix Transit WoesWill Americans Ever Lose Their Taste for Telework?Churches

Read more